Exelixis Inc., of South San Francicso, added Jeffrey Latts as chief medical officer and senior vice president.

Galileo Laboratories Inc., of Santa Clara, Calif., elected Louis Lange to its board.

Genaera Corp., of Plymouth Meeting, Pa., appointed Stephen Rennard, Jack Elias, Romain Pauwels, Gerry McElvaney and Qutayba Hamid to its respiratory development advisory board.

Genomic Profiling Systems Inc., of Cambridge, Mass., appointed Robert Linke president.

Gerard Klauer Mattison, of New York, added Kenneth Lerner to its healthcare investment banking group.

Geron Corp., of Menlo Park, Calif., appointed Patrick Zenner to its board.

Helix BioMedix Inc., of New Orleans, established a scientific advisory board, consisting of William Baker, Robin Cooper, R.E.W. Hancock and Arnold Smith.

Hyseq Inc., of Sunnyvale, Calif., added Li-Hsien Rin-Laures as senior vice president and general counsel.

Iconix Pharmaceuticals Inc., of Mountain View, Calif., appointed Michael James and John Walker to its board.

IDEC Pharmaceuticals Corp., of San Diego, appointed Michael Wiebe vice president, quality.

IngleWood Ventures, of San Diego, promoted Killu Tougu Sanborn to principal.

Ixion Biotechnology Inc., of Alachua, Fla., elected Hakan Edstrom to its board.

Maxygen Inc., of Redwood City, Calif., appointed Ernest Mario to its board.

MDS Pharma Services, of Montreal, added Victoria Wray as business development director for bioanalytical; named Gary Caulfield business development director for early clinical research, European operations; named Frank Marchesani business development director for biosafety and fermentation technologies; and named Lorella Donato senior director of the ligand services group at its St. Laurent site. Also, it added Tim Shull as business development representative covering the southwest United States.

Milkhaus Laboratory Inc., of Providence, R.I., elected Romeo Bachand to its board.

Palatin Technologies Inc., of Princeton, N.J., appointed Perry Molinoff executive vice president of research and development.

No Comments